Zydus Lifesciences revenue and financials
₹1,153.00Change from previous close: −0.56%Absolute change: −₹6.50
In the fiscal year ended March 2026, Zydus Lifesciences reported revenue of ₹267.2B (+18.37% year over year). Net income was ₹50.4B, a net margin of 18.9%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +18.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +11.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 18.9%
- FY to Mar 2025: 20.0%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total revenue | 78,020 | 74,344 | 67,804 | 64,670 | 62,902 |
| Cost of revenue | 22,398 | 19,763 | 18,363 | 17,895 | 16,971 |
| Gross profit | 55,622 | 54,581 | 49,441 | 46,775 | 45,931 |
| Operating income | 13,178 | 14,011 | 12,924 | 17,933 | 19,270 |
| EBIT | 14,626 | 17,827 | 14,833 | 20,053 | 17,486 |
| EBITDA | 20,173 | 22,911 | 18,429 | 22,434 | 19,865 |
| Interest expense | 1,560 | 1,230 | 1,299 | 847 | 766 |
| Pre-tax income | 13,066 | 16,597 | 13,534 | 19,206 | 16,720 |
| Income tax | 3,542 | 3,184 | 3,883 | 4,340 | 4,232 |
| Net income | 9,398 | 12,725 | 10,421 | 14,668 | 11,709 |
| Net income to common shareholders | 9,398 | 12,725 | 10,421 | 14,668 | 11,709 |
| Basic EPS | 9.35 | 12.65 | 10.36 | 14.58 | 11.64 |
| Diluted EPS | 9.35 | 12.65 | 10.36 | 14.58 | 11.64 |
| Average shares (basic) | 1,005 | 1,006 | 1,006 | 1,006 | 1,006 |
| Average shares (diluted) | 1,005 | 1,006 | 1,006 | 1,006 | 1,006 |